Companies Dominating the Neuroblastoma Landscape
- Merck & Co., Inc.,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- United Therapeutics Corporation
- APEIRON Biologics AG
- Sanofi S.A.
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Y- mabs Therapeutics Inc.
- Baxter International Inc.
- Cellectar Biosciences
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of neuroblastoma is estimated at USD 3.41 billion.
The neuroblastoma market size was over USD 3.17 billion in 2024 and is anticipated to cross USD 5.69 billion by 2037, growing at more than 4.6% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of neuroblastoma, the growing awareness about the disease, and the availability of new treatments will boost the market growth.
North America industry is likely to hold largest revenue share of 37% by 2037, backed by increasing healthcare expenditure, and the rising number of hospitals in the region
The major players in the market are Merck & Co., Inc., Pfizer Inc., United Therapeutics Corporation, APEIRON Biologics AG, Sanofi S.A., Bayer AG, Sun Pharmaceutical Industries Ltd., Y- mabs Therapeutics Inc., Baxter International Inc., Cellectar Biosciences
